
    
      This is a prospective, post market clinical follow-up (PMCF) multi-center, open-label study
      to evaluate the residual risk of injections of MONOVISC for relief of pain in patients with a
      diagnosis of an osteoarthritic hip joint.

      The subjects in this study will be patients with a diagnosis of osteoarthritic (OA) joint who
      the investigator determines are appropriate candidates for treatment with a viscoelastic
      injection of MONOVISC.

      Up to 25 subjects will be enrolled at up to 20 investigational sites in the EU. Subject
      participation will last approximately 6 Months, with visits scheduled at Screening, Baseline,
      1 month, 3 month and 6 months.
    
  